First Week of AMLX March 20th Options Trading

Amylyx Pharmaceuticals (AMLX) option setups: selling the $13.00 put (bid $0.80) against the $13.84 stock would set an effective cost basis of $12.20 and is estimated to have a 63% chance to expire worthless, representing a 6.15% return on cash (35.68% annualized) if it does. Alternatively, a covered call at the $15.00 strike (bid $0.65) would produce a 13.08% total return if called at the March 20 expiration, with a 52% chance to expire worthless and a 4.70% boost (27.23% annualized); implied vol for both contracts is ~91% versus a trailing 12‑month volatility of 72%, and Stock Options Channel will track probabilities and contract histories over time.

Analysis

Market structure: Short-dated option sellers and yield hunters win: selling the AMLX $13 put nets $0.80 (cost basis $12.20) and selling the $15 call nets $0.65, producing 6.15% and 4.70% cash boosts to March 20 expiry (annualized 35.7% and 27.2%). Directional longs and buy-and-hold traders lose optional upside if assigned; exchanges (NDAQ) and market-makers benefit from trading/fee flow. The market is pricing elevated hedging demand—IV ~91% vs realized 72% (19ppt gap), signalling disproportionate demand for downside protection relative to realized movement.

Risk assessment: Tail risk remains high for AMLX as a small-cap biotech—binary regulatory/trial outcomes can move price >50% in a single event; model this as >±2σ moves given current IV. Immediate risk (days): gamma into March expiry; short-term (weeks): time decay benefits sellers but IV crush on positive news hurts short-sellers; long-term (quarters): dilution or partnership news can materially change fundamentals. Hidden dependencies include options liquidity, borrow costs, and financing risk if assigned shares force cash deployment or trigger margin calls.

Trade implications: Direct play—cash-secured sell-to-open AMLX $13 puts to collect $0.80 for investors willing to own at $12.20 (limit position to 1–3% portfolio, reassess if assigned). Covered-call play—buy AMLX and sell $15 Mar20 calls to capture ~13.1% capped return; close/roll if stock >$16 or IV compresses >10ppt. Vol strategy—opportunistic short premium (defined-risk iron condor/short strangle) because IV>realized, size 0.5–1% portfolio and cap max loss at 3x premium.

Contrarian angles: The consensus to sell premium underprices the binary risk that justifies the IV gap—if a readout/FDA date is within 30–90 days, IV may remain elevated or spike, making short-premium trades dangerous. Historical parallels: pre-readout small-cap biotechs often see rapid IV collapse on neutral/positive news and catastrophic drops on negative news—expect asymmetric payoff. Unintended consequence: assignment at $13 forces capital deployment and potential exposure to dilution; require stop/roll rules (e.g., buy protection if stock < $10).

Key Decisions for Investors

• Sell cash-secured AMLX $13 puts (Mar20) to collect $0.80 with position sizing 1–3% of portfolio; set hard buy-to-close if AMLX falls below $10 or if IV spikes >+15ppt; treat assignment as intention to own at $12.20.
• Initiate covered-call: buy AMLX up to 2% portfolio and sell $15 Mar20 calls for ~$0.65; target realized return 13.1% through expiry; close/roll if stock >$16 or if IV compresses by >10ppt pre-expiry.
• Construct a defined-risk iron condor/short strangle on AMLX (60–90 day expiries) only if IV >85% and IV - realized >15ppt; limit allocation to 0.5–1% portfolio and cap max loss at 3x collected premium.
• Within 30–90 days, monitor FDA/trial milestones and volume spikes: reduce short-premium exposure by 50% starting 30 days before any confirmed binary announcement; convert to long-protection (buy puts) if a negative readout probability >30% is implied by options pricing.